| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| NAGENiagen Bioscience Inc | 503.58M | 6.31 | 57.36 | 19.18% | 16.38% | 28.91% | 2.37% | 0.06 |
| BTXBlackRock Technology and Private Equity Term Trust | 808.8M | 6.93 | 40.76 | -81.13% | 87.75% | 1.87% | 34.27% | |
| HALOHalozyme Therapeutics, Inc. | 8.45B | 71.82 | 20.94 | 22.44% | 47.91% | 118.17% | 5.55% | 4.14 |
| RPRXRoyalty Pharma plc | 16.97B | 39.72 | 20.80 | -3.86% | 32.55% | 7.95% | 16.32% | 0.74 |
| REGNRegeneron Pharmaceuticals, Inc. | 76.63B | 741.92 | 19.35 | 8.27% | 32.13% | 14.79% | 4.78% | 0.09 |
| GMABGenmab A/S | 20.85B | 33.85 | 2.79 | 30.67% | 46.8% | 114.25% | 36.37% | 0.03 |
| DNAGinkgo Bioworks Holdings, Inc. | 464.86M | 9.58 | -0.91 | -9.71% | -188% | -60.66% | 0.65 | |
| PRMEPrime Medicine, Inc. | 720.24M | 3.99 | -2.42 | -33.02% | -121.95% | 0.27 |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 173.6M | 190.93M | 230.98M | 160.57M | 31.99M | 31.99M | 14.27M | 26.91M | 6.22M | 3.92M |
| Revenue Growth % | 1.41% | 0.1% | 0.21% | -0.3% | -0.8% | 0% | -0.55% | 0.89% | -0.77% | -0.37% |
| Cost of Goods Sold | 63.93M | 61.64M | 62.79M | 63.29M | 5.37M | 44.8M | 53.68M | 6.34M | 6.12M | 4.27M |
| COGS % of Revenue | 0.37% | 0.32% | 0.27% | 0.39% | 0.17% | 1.4% | 3.76% | 0.24% | 0.98% | 1.09% |
| Gross Profit | 109.68M | 129.29M | 168.19M | 97.29M | 26.62M | -12.81M | -39.41M | 20.57M | 106K | -342K |
| Gross Margin % | 0.63% | 0.68% | 0.73% | 0.61% | 0.83% | -0.4% | -2.76% | 0.76% | 0.02% | -0.09% |
| Gross Profit Growth % | 1.08% | 0.18% | 0.3% | -0.42% | -0.73% | -1.48% | -2.08% | 1.52% | -0.99% | -4.23% |
| Operating Expenses | 256.54M | 254.45M | 289.31M | 542.39M | 112.94M | 73.51M | 52.54M | 96.3M | 99.86M | 134.69M |
| OpEx % of Revenue | 1.48% | 1.33% | 1.25% | 3.38% | 3.53% | 2.3% | 3.68% | 3.58% | 16.04% | 34.32% |
| Selling, General & Admin | 109.06M | 142.32M | 146.1M | 137.81M | 72.69M | 0 | 0 | 48.01M | 40.41M | 41.29M |
| SG&A % of Revenue | 0.63% | 0.75% | 0.63% | 0.86% | 2.27% | - | - | 1.78% | 6.49% | 10.52% |
| Research & Development | 147.48M | 112.14M | 143.21M | 404.59M | 39.43M | 39.43M | 47.93M | 47.17M | 48.61M | 53.07M |
| R&D % of Revenue | 0.85% | 0.59% | 0.62% | 2.52% | 1.23% | 1.23% | 3.36% | 1.75% | 7.81% | 13.52% |
| Other Operating Expenses | 1.31M | 1.7M | 1.01M | 630K | 814K | 34.08M | 4.6M | 1.12M | 10.84M | 40.32M |
| Operating Income | -146.86M | -125.17M | -137.89M | -505.61M | -86.32M | -86.32M | -91.95M | -75.73M | -99.76M | -135.03M |
| Operating Margin % | -0.85% | -0.66% | -0.6% | -3.15% | -2.7% | -2.7% | -6.44% | -2.81% | -16.03% | -34.4% |
| Operating Income Growth % | -1.1% | 0.15% | -0.1% | -2.67% | 0.83% | 0% | -0.07% | 0.18% | -0.32% | -0.35% |
| EBITDA | -129.12M | -100.59M | -106.75M | -481.5M | -68.8M | -68.8M | -78.19M | -64.96M | -93.09M | -130.5M |
| EBITDA Margin % | -0.74% | -0.53% | -0.46% | -3% | -2.15% | -2.15% | -5.48% | -2.41% | -14.95% | -33.25% |
| EBITDA Growth % | -1.17% | 0.22% | -0.06% | -3.51% | 0.86% | 0% | -0.14% | 0.17% | -0.43% | -0.4% |
| D&A (Non-Cash Add-back) | 17.74M | 24.57M | 31.14M | 24.11M | 17.52M | 17.52M | 13.76M | 10.77M | 6.67M | 4.53M |
| EBIT | -85.73M | -193.29M | -129.09M | -387.44M | -86.31M | -85.5M | -91.41M | -73.19M | -95.89M | -128.02M |
| Net Interest Income | 640K | 9.33M | 18.85M | 10.54M | -17.2M | -15.95M | -18.58M | -6.64M | 2.77M | 1.41M |
| Interest Income | 1.88M | 10.19M | 19.48M | 19.08M | 1.01M | 2.45M | 171K | 133K | 3.24M | 1.42M |
| Interest Expense | 1.24M | 861K | 611K | 8.53M | 18.21M | 18.4M | 18.75M | 6.77M | 468K | 6K |
| Other Income/Expense | 59.89M | -68.98M | 17.8M | -26.25M | -18.21M | -18.21M | -19.02M | -4.24M | 3.4M | 7M |
| Pretax Income | -86.98M | -194.15M | -129.7M | -536.23M | -104.52M | -104.52M | -110.97M | -79.97M | -96.36M | -128.03M |
| Pretax Margin % | -0.5% | -1.02% | -0.56% | -3.34% | -3.27% | -3.27% | -7.78% | -2.97% | -15.48% | -32.62% |
| Income Tax | 1.02M | -3.88M | -2.88M | -21.53M | -82K | -82K | -160K | -189K | -458K | -1.79M |
| Effective Tax Rate % | 0.97% | 0.96% | 0.9% | 0.95% | 1.63% | 1.63% | 0.83% | -0.35% | 1% | 0.99% |
| Net Income | -84.49M | -186.61M | -117.02M | -509.34M | -170.52M | -170.52M | -92.17M | 28.32M | -95.9M | -126.23M |
| Net Margin % | -0.49% | -0.98% | -0.51% | -3.17% | -5.33% | -5.33% | -6.46% | 1.05% | -15.41% | -32.16% |
| Net Income Growth % | -0.03% | -1.21% | 0.37% | -3.35% | 0.67% | 0% | 0.46% | 1.31% | -4.39% | -0.32% |
| Net Income (Continuing) | -87.99M | -190.27M | -126.82M | -380.49M | -104.44M | -104.44M | -110.81M | -79.78M | -95.9M | -126.23M |
| Discontinued Operations | 0 | 0 | 0 | 0 | -66.08M | -66.08M | 18.64M | 108.09M | 0 | 0 |
| Minority Interest | 10.81M | 9.01M | 12.91M | 15.87M | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.76 | -1.58 | -0.98 | -3.93 | -1.35 | -1.02 | -0.47 | -0.33 | -0.39 | -0.47 |
| EPS Growth % | 0.08% | -1.08% | 0.38% | -3.01% | 0.66% | 0.24% | 0.54% | 0.3% | -0.18% | -0.21% |
| EPS (Basic) | -0.76 | -1.58 | -0.98 | -3.93 | -1.35 | -1.02 | -0.47 | -0.33 | -0.39 | -0.47 |
| Diluted Shares Outstanding | 111.07M | 117.98M | 120M | 129.52M | 154.14M | 167.07M | 197.76M | 200.36M | 244.54M | 267.73M |
| Basic Shares Outstanding | 111.07M | 117.98M | 120M | 129.52M | 154.14M | 167.07M | 197.76M | 200.36M | 244.54M | 267.73M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 323.8M | 315.18M | 154.05M | 285.48M | 234.64M | 148.95M | 156.63M | 118.16M | 68.75M | 102.41M |
| Cash & Short-Term Investments | 238.31M | 237.21M | 79.67M | 222.84M | 75.05M | 100.12M | 108.66M | 55.95M | 62.85M | 97.91M |
| Cash Only | 135.78M | 62.61M | 68.11M | 102.77M | 65.79M | 51.79M | 36.42M | 4.86M | 7.58M | 29.52M |
| Short-Term Investments | 102.53M | 174.6M | 11.56M | 120.07M | 9.26M | 48.33M | 72.24M | 51.09M | 55.28M | 68.39M |
| Accounts Receivable | 52.29M | 42.48M | 39.84M | 26.57M | 26.22M | 20.43M | 1.98M | 13.8M | 1.57M | 1.16M |
| Days Sales Outstanding | 109.95 | 81.22 | 62.96 | 60.38 | 299.17 | 233.05 | 50.66 | 187.24 | 92.35 | 108.15 |
| Inventory | 26.56M | 21.14M | 20.49M | 21.45M | 16.1M | 11.36M | 326K | 287K | 0 | 0 |
| Days Inventory Outstanding | 151.66 | 125.18 | 119.13 | 123.69 | 1.09K | 92.54 | 2.22 | 16.53 | - | - |
| Other Current Assets | 0 | 6.99M | 6.99M | 16.14M | 111.44M | 9.85M | 38.92M | 48.12M | 4.33M | 3.34M |
| Total Non-Current Assets | 658.25M | 633.89M | 692.8M | 430.69M | 221.12M | 165.64M | 203.23M | 97.82M | 82.29M | 42.85M |
| Property, Plant & Equipment | 42.74M | 64.67M | 112.67M | 128.87M | 86.2M | 44.28M | 18.55M | 15.29M | 14.13M | 18.8M |
| Fixed Asset Turnover | 4.06x | 2.95x | 2.05x | 1.25x | 0.37x | 0.72x | 0.77x | 1.76x | 0.44x | 0.21x |
| Goodwill | 165.17M | 157.18M | 153.29M | 149.59M | 63.75M | 54.36M | 37.55M | 36.92M | 26.61M | 19.14M |
| Intangible Assets | 247.53M | 225.62M | 232.88M | 129.29M | 68.35M | 65.4M | 52.29M | 44.45M | 40.7M | 4.46M |
| Long-Term Investments | 199.08M | 182.72M | 189.91M | 20.85M | 1.46M | 0 | 48.56M | 399K | 0 | 0 |
| Other Non-Current Assets | 3.73M | 3.71M | 4.05M | -6.33M | -13.88M | -8.12M | 46.27M | -8.42M | 846K | 459K |
| Total Assets | 982.05M | 949.07M | 846.85M | 716.18M | 455.76M | 314.59M | 359.86M | 215.98M | 151.04M | 145.27M |
| Asset Turnover | 0.18x | 0.20x | 0.27x | 0.22x | 0.07x | 0.10x | 0.04x | 0.12x | 0.04x | 0.03x |
| Asset Growth % | 0.7% | -0.03% | -0.11% | -0.15% | -0.36% | -0.31% | 0.14% | -0.4% | -0.3% | -0.04% |
| Total Current Liabilities | 75.9M | 94.61M | 80.17M | 61.56M | 122.91M | 42.13M | 34.65M | 78.64M | 22.98M | 21.52M |
| Accounts Payable | 4.97M | 8.48M | 8.7M | 11.97M | 5.53M | 4.6M | 3.11M | 4.07M | 1.73M | 3.53M |
| Days Payables Outstanding | 28.36 | 50.2 | 50.58 | 69.05 | 375.46 | 37.46 | 21.16 | 234.24 | 102.96 | 302.04 |
| Short-Term Debt | 1.49M | 1.21M | 735K | 945K | 33.59M | 360K | 52K | 43.22M | 0 | 0 |
| Deferred Revenue (Current) | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 25K | 509K | 589K |
| Other Current Liabilities | 15.03M | 24.58M | 21.08M | 27.34M | 62.21M | 22.14M | 20.71M | 23.75M | 8.25M | 8.42M |
| Current Ratio | 4.27x | 3.33x | 1.92x | 4.64x | 1.91x | 3.54x | 4.52x | 1.50x | 2.99x | 4.76x |
| Quick Ratio | 3.92x | 3.11x | 1.67x | 4.29x | 1.78x | 3.27x | 4.51x | 1.50x | 2.99x | 4.76x |
| Cash Conversion Cycle | 233.25 | 156.19 | 131.51 | 115.02 | 1.02K | 288.14 | 31.71 | -30.47 | - | - |
| Total Non-Current Liabilities | 201.26M | 285.21M | 220.13M | 275.89M | 261.14M | 205.29M | 217.86M | 11.07M | 9.56M | 85.23M |
| Long-Term Debt | 7.6M | 7.56M | 7.54M | 211.22M | 186.32M | 171.52M | 179.88M | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 10.12M | 7.74M | 8.75M | 6.99M | 5.89M | 4.55M |
| Deferred Tax Liabilities | 21.8M | 17.01M | 15.62M | 7.21M | 2.83M | 2.9M | 2.54M | 2.26M | 1.85M | 0 |
| Other Non-Current Liabilities | 9.49M | 3.87M | 3.45M | 64.68M | 13.73M | 100K | 3.67M | 0 | 0 | 78.75M |
| Total Liabilities | 277.16M | 379.82M | 300.31M | 337.45M | 384.05M | 247.41M | 252.51M | 89.72M | 32.55M | 106.75M |
| Total Debt | 9.09M | 8.77M | 8.27M | 212.26M | 232.67M | 182.28M | 190.07M | 51.42M | 7.1M | 5.5M |
| Net Debt | -126.69M | -53.84M | -59.84M | 109.49M | 166.87M | 130.49M | 153.65M | 46.56M | -481K | -24.02M |
| Debt / Equity | 0.01x | 0.02x | 0.02x | 0.56x | 3.24x | 2.71x | 1.77x | 0.41x | 0.06x | 0.14x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest Coverage | -118.06x | -145.37x | -225.68x | -59.27x | -4.74x | -4.69x | -4.90x | -11.18x | -213.16x | -22504.83x |
| Total Equity | 704.89M | 569.25M | 546.54M | 378.72M | 71.71M | 67.17M | 107.35M | 126.26M | 118.5M | 38.51M |
| Equity Growth % | 0.72% | -0.19% | -0.04% | -0.31% | -0.81% | -0.06% | 0.6% | 0.18% | -0.06% | -0.67% |
| Book Value per Share | 6.35 | 4.82 | 4.55 | 2.92 | 0.47 | 0.40 | 0.54 | 0.63 | 0.48 | 0.14 |
| Total Shareholders' Equity | 694.08M | 560.24M | 533.63M | 362.86M | 71.71M | 67.17M | 107.35M | 126.26M | 118.5M | 38.51M |
| Common Stock | 0 | 580.07M | 580.07M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Retained Earnings | -542.73M | -729.34M | -847.82M | -1.33B | -1.65B | -1.82B | -1.92B | -1.87B | -1.96B | -2.09B |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -12.75M | -36.2M | -15.55M | -28.61M | -27.47M | 4M | 203K | -3.49M | -1.95M | 12K |
| Minority Interest | 10.81M | 9.01M | 12.91M | 15.87M | 0 | 0 | 0 | 0 | 0 | 0 |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | 35.67M | -55.98M | -104.14M | -124.24M | -77.02M | -77.02M | -55.77M | -65.05M | -66.93M | -68.17M |
| Operating CF Margin % | 0.21% | -0.29% | -0.45% | -0.77% | -2.41% | -2.41% | -3.91% | -2.42% | -10.75% | -17.37% |
| Operating CF Growth % | 2.8% | -2.57% | -0.86% | -0.19% | 0.38% | 0% | 0.28% | -0.17% | -0.03% | -0.02% |
| Net Income | -87.99M | -190.27M | -126.82M | -514.71M | -170.52M | -170.52M | -92.17M | 28.32M | -95.9M | -126.23M |
| Depreciation & Amortization | 17.74M | 24.57M | 31.14M | 33.11M | 17.52M | 17.52M | 13.76M | 10.77M | 6.67M | 4.53M |
| Stock-Based Compensation | 100.42M | 52.98M | 52.69M | 46.99M | 18.37M | 18.37M | 13.9M | 10.21M | 9.89M | 9.47M |
| Deferred Taxes | 1.12M | -3.47M | -2.53M | -21.28M | -156K | -156K | -167K | -150K | -479K | -1.79M |
| Other Non-Cash Items | -54.44M | 77.95M | 15.95M | 351.63M | 78.42M | 78.42M | 9.7M | -78.48M | -4.17M | 41.34M |
| Working Capital Changes | 58.83M | -17.74M | -74.58M | -19.98M | -20.65M | -20.65M | -804K | -35.7M | 17.07M | 4.52M |
| Change in Receivables | -12.14M | 2.59M | 740K | -2.7M | 4.33M | 4.33M | -6.56M | -13.51M | 12.23M | 414K |
| Change in Inventory | -774K | 3.81M | 663K | -478K | 2.51M | 2.51M | -1.9M | 2.34M | 0 | 0 |
| Change in Payables | -3.26M | 3.62M | -3.4M | 4.68M | -1.1M | -1.1M | 420K | 379K | -2.42M | 1.55M |
| Cash from Investing | -260.81M | -28.39M | 104.33M | -151.21M | 27.78M | 27.78M | -74.54M | 226.42M | -3.09M | -20.71M |
| Capital Expenditures | -12.75M | -31.63M | -46.67M | -41.59M | -7.53M | -7.53M | -7.25M | -4.92M | -1.54M | -8.58M |
| CapEx % of Revenue | 0.07% | 0.17% | 0.2% | 0.26% | 0.24% | 0.24% | 0.51% | 0.18% | 0.25% | 2.19% |
| Acquisitions | - | - | - | - | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | -40K | -2.69M | 736K | 17.77M | 84.5M | 73.67M | 6.76M | 162.9M | 98K | 60K |
| Cash from Financing | 333.25M | 12.06M | 4.28M | 309.8M | 32.7M | 32.7M | 121.19M | -155.29M | 29.59M | 110.58M |
| Debt Issued (Net) | - | - | - | - | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - | - | - | - | - | - |
| Other Financing | -6.25M | 12.46M | -8.62M | 2.34M | 117K | 117K | 608K | 1K | 0 | 346K |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | 22.92M | -87.6M | -150.81M | -165.83M | -84.55M | -84.55M | -63.02M | -69.97M | -68.47M | -76.76M |
| FCF Margin % | 0.13% | -0.46% | -0.65% | -1.03% | -2.64% | -2.64% | -4.42% | -2.6% | -11% | -19.56% |
| FCF Growth % | 1.87% | -4.82% | -0.72% | -0.1% | 0.49% | 0% | 0.25% | -0.11% | 0.02% | -0.12% |
| FCF per Share | 0.21 | -0.74 | -1.26 | -1.28 | -0.55 | -0.51 | -0.32 | -0.35 | -0.28 | -0.29 |
| FCF Conversion (FCF/Net Income) | -0.42x | 0.30x | 0.89x | 0.24x | 0.45x | 0.45x | 0.61x | -2.30x | 0.70x | 0.54x |
| Interest Paid | 1.2M | 964K | 617K | 3.87M | 7.2M | 7.2M | 7.16M | 8.54M | 1.17M | 7K |
| Taxes Paid | 1.17M | 10K | 566K | 216K | 48K | 48K | 36K | 0 | 21K | 4K |
| Metric | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -15.17% | -29.29% | -20.97% | -110.09% | -75.71% | -245.56% | -105.62% | 24.24% | -78.37% | -160.8% |
| Return on Invested Capital (ROIC) | -22.65% | -17.17% | -20.64% | -77.79% | -17.81% | -29.68% | -30.07% | -26.18% | -51.45% | -152.85% |
| Gross Margin | 63.18% | 67.72% | 72.82% | 60.59% | 83.2% | -40.04% | -276.24% | 76.44% | 1.7% | -8.71% |
| Net Margin | -48.67% | -97.74% | -50.66% | -317.2% | -533.01% | -533.01% | -646.01% | 105.23% | -1540.63% | -3216.18% |
| Debt / Equity | 0.01x | 0.02x | 0.02x | 0.56x | 3.24x | 2.71x | 1.77x | 0.41x | 0.06x | 0.14x |
| Interest Coverage | -118.06x | -145.37x | -225.68x | -59.27x | -4.74x | -4.69x | -4.90x | -11.18x | -213.16x | -22504.83x |
| FCF Conversion | -0.42x | 0.30x | 0.89x | 0.24x | 0.45x | 0.45x | 0.61x | -2.30x | 0.70x | 0.54x |
| Revenue Growth | 141.35% | 9.98% | 20.98% | -30.48% | -80.08% | 0% | -55.4% | 88.61% | -76.87% | -36.95% |
| 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Exemplar | - | - | - | - | - | - | - | - | - | 3.92M |
| Exemplar Growth | - | - | - | - | - | - | - | - | - | - |
| Upfront And Milestone Payments | - | - | - | - | 63.28M | 50.59M | 25M | 2.03M | 16.01M | - |
| Upfront And Milestone Payments Growth | - | - | - | - | - | -20.05% | -50.58% | -91.87% | 686.97% | - |
| Collaboration and licensing agreements | - | - | - | - | 16.3M | 2.17M | - | - | - | - |
| Collaboration and licensing agreements Growth | - | - | - | - | - | -86.68% | - | - | - | - |
| Service | - | - | - | - | 52.42M | - | - | - | - | - |
| Service Growth | - | - | - | - | - | - | - | - | - | - |
| Product | - | - | - | - | 28.53M | - | - | - | - | - |
| Product Growth | - | - | - | - | - | - | - | - | - | - |
| Other | - | - | - | - | 2.76M | - | - | - | - | - |
| Other Growth | - | - | - | - | - | - | - | - | - | - |
| Research And Development Services | - | 55.31M | 75.44M | 73.94M | - | - | - | - | - | - |
| Research And Development Services Growth | - | - | 36.40% | -1.98% | - | - | - | - | - | - |
| Prepaid Product And Service Revenues | 4.37M | - | - | - | - | - | - | - | - | - |
| Prepaid Product And Service Revenues Growth | - | - | - | - | - | - | - | - | - | - |
| Prepaid Research And Development Services | 1.04M | - | - | - | - | - | - | - | - | - |
| Prepaid Research And Development Services Growth | - | - | - | - | - | - | - | - | - | - |
| Deferred Revenue Other | 571K | - | - | - | - | - | - | - | - | - |
| Deferred Revenue Other Growth | - | - | - | - | - | - | - | - | - | - |
| 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Non-US | - | 5.92M | 11.97M | 17.61M | 11.95M | 1.4M | 595K | 530K | 233K | - |
| Non-US Growth | - | - | 102.25% | 47.09% | -32.15% | -88.27% | -57.53% | -10.92% | -56.04% | - |
| Foreign Countries | 2.17M | - | - | - | - | - | - | - | - | - |
| Foreign Countries Growth | - | - | - | - | - | - | - | - | - | - |
Precigen, Inc. (PGEN) reported $6.3M in revenue for fiscal year 2024. This represents a 21% decrease from $8.0M in 2011.
Precigen, Inc. (PGEN) saw revenue decline by 36.9% over the past year.
Precigen, Inc. (PGEN) reported a net loss of $246.9M for fiscal year 2024.
Precigen, Inc. (PGEN) has a return on equity (ROE) of -160.8%. Negative ROE indicates the company is unprofitable.
Precigen, Inc. (PGEN) had negative free cash flow of $75.6M in fiscal year 2024, likely due to heavy capital investments.